rilotumumab

a fully human monoclonal antibody that binds to hepatocyte growth factor (HGF), a potential cancer therapeutic agent because of its ability to disrupt HGF/c-Met signaling pathways which have been implicated in most tumor types

Also Known As:

Networked: 42 relevant articles (8 outcomes, 27 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Zhu, Min: 10 articles (11/2017 - 01/2010)
2.	Oliner, Kelly S: 9 articles (06/2015 - 01/2010)
3.	Burgess, Teresa L: 7 articles (05/2013 - 11/2007)
4.	Tang, Rui: 6 articles (11/2017 - 01/2013)
5.	Zhang, Yilong: 6 articles (11/2017 - 01/2014)
6.	Loh, Elwyn: 6 articles (06/2015 - 04/2011)
7.	Coxon, Angela: 6 articles (05/2013 - 11/2007)
8.	Anderson, Abraham: 5 articles (08/2014 - 01/2010)
9.	Zhang, Y: 3 articles (02/2020 - 02/2015)
10.	Davidenko, Irina: 3 articles (11/2017 - 08/2014)

Related Diseases

1.	Neoplasms (Cancer) 05/01/2013 - "In the dose response study, rilotumumab at doses of 300 and 500 μg was similarly effective against tumor growth. " 03/01/2014 - "The study utilized co-dual primary endpoints of tumor response and six-month PFS to assess the efficacy of rilotumumab. " 05/01/2013 - "The purpose of this study was to evaluate the efficacy of rilotumumab in a U-87 MG mouse xenograft tumor model using (18)F-FDG and (18)F-FLT PET. " 11/01/2015 - "Over the last decade, rilotumumab has been extensively tested in preclinical studies and in clinical studies in a variety of cancer types. " 06/01/2015 - "Rilotumumab concentrations, tumor sizes, and survival time from the phase II study were pooled to develop a longitudinal exposure versus TG model and parametric OS model that explored predictive/prognostic/treatment effects (MET expression, rilotumumab exposure, relative tumor size). "
2.	Adenocarcinoma 01/01/2019 - "FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial." 11/01/2017 - "Ligand-blocking inhibition of the MET pathway with rilotumumab is not effective in improving clinical outcomes in patients with MET-positive gastric or gastro-oesophageal adenocarcinoma. " 01/01/2019 - "We found no benefit in adding panitumumab or rilotumumab to mFOLFOX6 first-line chemotherapy to treat advanced gastroesophageal adenocarcinoma patients. " 08/01/2014 - "Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study." 11/01/2017 - "We aimed to assess the efficacy, safety, and pharmacokinetics of rilotumumab combined with epirubicin, cisplatin, and capecitabine, and to assess potential biomarkers, in patients with advanced MET-positive gastric or gastro-oesophageal junction adenocarcinoma. "
3.	Stomach Neoplasms (Stomach Cancer) 01/01/2014 - "Here we discuss the background to the treatment of gastric cancer as well as the characteristics of rilotumumab and reported results with this agent in the trials performed to date. " 06/01/2015 - "Rilotumumab exposure-response relationship in patients with advanced or metastatic gastric cancer." 02/03/2015 - "Exposure-response analysis of rilotumumab in gastric cancer: the role of tumour MET expression." 09/01/2014 - "Rilotumumab extends PFS in gastric cancer." 01/01/2014 - "Potential role of rilotumumab in the treatment of gastric cancer."
4.	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 11/01/2017 - "A Randomized, Placebo-Controlled, Phase 1b/2 Study of Rilotumumab or Ganitumab in Combination With Platinum-Based Chemotherapy as First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer." 11/01/2017 - "In this randomized, double-blind, placebo-controlled phase 1b/2 study we assessed the efficacy/safety of rilotumumab or ganitumab combined with etoposide and carboplatin or cisplatin as first-line treatment in patients with extensive stage small-cell lung cancer (ES-SCLC). "
5.	Glioblastoma (Glioblastoma Multiforme) 09/01/2011 - "We investigated the effects of the anti-HGF monoclonal antibody, AMG102, on the response to ionizing radiation in a model of glioblastoma multiforme in vitro and in vivo. " 01/11/2023 - "To anticipate and study specific resistance mechanisms associated with targeting this pathway, we engineered resistance to the HGF-neutralizing antibody rilotumumab in glioblastoma cells harboring autocrine HGF/Met signaling, a frequent abnormality of this brain cancer in humans. " 04/01/2011 - "A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma." 04/01/2011 - "This phase II study evaluated the efficacy and safety of AMG 102 (rilotumumab), a fully human monoclonal antibody against hepatocyte growth factor/scatter factor (HGF/SF), in patients with recurrent glioblastoma (GBM). "

Related Drugs and Biologics

1.	Cisplatin (Platino)
2.	Capecitabine (Xeloda)
3.	Epirubicin (Ellence)
4.	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)
5.	Monoclonal Antibodies
6.	Panitumumab (Vectibix)
7.	ganitumab
8.	Platinum
9.	Etoposide (VP 16)
10.	Carboplatin (JM8)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Therapeutics
3.	Castration
4.	Combination Drug Therapy (Combination Chemotherapy)
5.	Aftercare (After-Treatment)